NBK/BIK antagonizes MCL-1 and BCL-XL and activates BAK-mediated apoptosis in response to protein synthesis inhibition

被引:110
|
作者
Shimazu, Tsutomu
Degenhardt, Kurt
Nur-E-Kamal, Alam
Zhang, Junjie
Yoshida, Takeshi
Zhang, Yonglong
Mathew, Robin
White, Eileen [1 ]
Inouye, Masayori
机构
[1] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA
[2] Rutgers State Univ, Ctr Adv Biotechnol & Med, Dept Mol Biol & Biochem, Piscataway, NJ 08854 USA
[3] Canc Inst New Jersey, New Brunswick, NJ 08903 USA
关键词
NBK/BIK; BAK; mRNA interferase; apoptosis;
D O I
10.1101/gad.1522007
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Ribonucleases, antibiotics, bacterial toxins, and viruses inhibit protein synthesis, which results in apoptosis in mammalian cells. How the BCL-2 family of proteins regulates apoptosis in response to the shutoff of protein synthesis is not known. Here we demonstrate that an Escherichia coli toxin, MazF, inhibited protein synthesis by cleavage of cellular mRNA and induced apoptosis in mammalian cells. MazF-induced apoptosis required proapoptotic BAK and its upstream regulator, the proapoptotic BH3-only protein NBK/BIK, but not BIM, PUMA, or NOXA. Interestingly, in response to MazF induction, NBK/BIK activated BAK by displacing it from anti-apoptotic proteins MCL-1 and BCL-X-L that sequester BAK. Furthermore, NBK/BIK- or BAK-deficient cells were resistant to cell death induced by pharmacologic inhibition of translation and by virus-mediated shutoff of protein synthesis. Thus, the BH3-only protein NBK/BIK is the apical regulator of a BAK-dependent apoptotic pathway in response to shutoff of protein synthesis that functions to displace BAK from sequestration by MCL1 and BCL-X-L. Although NBK/BIK is dispensable for development, it is the BH3- only protein targeted for inactivation by viruses, suggesting that it plays a role in pathogen/toxin response through apoptosis activation.
引用
收藏
页码:929 / 941
页数:13
相关论文
共 50 条
  • [31] MCL-1, BCL-XL and MITF Are Diversely Employed in Adaptive Response of Melanoma Cells to Changes in Microenvironment
    Hartman, Mariusz L.
    Talar, Beata
    Gajos-Michniewicz, Anna
    Czyz, Malgorzata
    PLOS ONE, 2015, 10 (06):
  • [32] MicroRNA-133a, downregulated in osteosarcoma, suppresses proliferation and promotes apoptosis by targeting Bcl-xL and Mcl-1
    Ji, Fang
    Zhang, Hao
    Wang, Yang
    Li, Ming
    Xu, Weidong
    Kang, Yifan
    Wang, Zhiwei
    Wang, Zimin
    Cheng, Ping
    Tong, Dake
    Li, Cheng
    Tang, Hao
    BONE, 2013, 56 (01) : 220 - 226
  • [33] From meiogynin A to the synthesis of dual inhibitors of Bcl-xL and Mcl-1 anti-apoptotic proteins
    Desrat, S.
    Remeur, C.
    Geny, C.
    Riviere, G.
    Colas, C.
    Dumontet, V.
    Birlirakis, N.
    Iorga, B. I.
    Roussi, F.
    CHEMICAL COMMUNICATIONS, 2014, 50 (62) : 8593 - 8596
  • [34] Anti-apoptotic Bcl-XL but not Mcl-1 contributes to protection against virus-induced apoptosis
    Ohmer, Michaela
    Weber, Arnim
    Sutter, Gerd
    Ehrhardt, Katrin
    Zimmermann, Albert
    Haecker, Georg
    CELL DEATH & DISEASE, 2016, 7 : e2340 - e2340
  • [35] Anti-apoptotic Bcl-XL but not Mcl-1 contributes to protection against virus-induced apoptosis
    Michaela Ohmer
    Arnim Weber
    Gerd Sutter
    Katrin Ehrhardt
    Albert Zimmermann
    Georg Häcker
    Cell Death & Disease, 2016, 7 : e2340 - e2340
  • [36] Concomitant inhibition of Bcl-xL and Mcl-1 expression by RNA interference as a novel strategy for the treatment of ovarian carcinomas
    Denoyelle, C.
    Brotin, E.
    Duval, R.
    Simonin, K.
    Meryet-Figuiere, M.
    N'Diaye, M.
    Louis, M. H.
    Dutoit, S.
    Gauduchon, P.
    Poulain, L.
    EJC SUPPLEMENTS, 2008, 6 (09): : 81 - 82
  • [37] Mcl-1, Bcl-xL and cell cycle inhibition by GCS-100:: A novel therapy for myeloma.
    Streetly, Matthew
    Su, Bo
    Carver, Bradley
    Schey, Stephen A.
    Cotter, Finbarr E.
    BLOOD, 2006, 108 (11) : 990A - 990A
  • [38] Inhibition of Mcl-1 expression by citrate enhances the effect of Bcl-xL inhibitors on human ovarian carcinoma cells
    Lincet, Hubert
    Kafara, Perrine
    Giffard, Florence
    Abeilard-Lemoisson, Edwige
    Duval, Maryline
    Louis, Marie-Helene
    Poulain, Laurent
    Icard, Philippe
    JOURNAL OF OVARIAN RESEARCH, 2013, 6
  • [39] Inhibition of Mcl-1 expression by citrate enhances the effect of Bcl-xL inhibitors on human ovarian carcinoma cells
    Hubert Lincet
    Perrine Kafara
    Florence Giffard
    Edwige Abeilard-Lemoisson
    Maryline Duval
    Marie-Hélène Louis
    Laurent Poulain
    Philippe Icard
    Journal of Ovarian Research, 6
  • [40] mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1
    Coffee, Erin M.
    Faber, Anthony C.
    Costa, Carlotta
    Dastur, Anahita
    Ebi, Hiromichi
    Hata, Aaron N.
    Yeo, Alan T.
    Elena, J.
    Song, Youngchul
    Tam, Ah Ting
    Boisvert, Jessica L.
    Milano, Randy J.
    Roper, Jatin
    Kodack, David P.
    Jain, Rakesh K.
    Corcoran, Ryan B.
    Rivera, Miguel N.
    Ramaswamy, Sridhar
    Hung, Kenneth E.
    Benes, Cyril H.
    Engelman, Jeffrey A.
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)